No Image Provided

EyeBiotech

VC Funding

Series A £50m+

Healthcare & Biotech Published 14 November 2023

Summary

In a significant market movement during November 2023, EyeBiotech was the subject of a vc funding. The transaction achieved a gross valuation of £52,871,596. Leading the round was SV Health Investors, Bain Capital Life Sciences, Samsara Biocapital, Omega Funds, Jeito Capital, MRL Ventures Fund, Vertex Ventures.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

SV Health Investors

Lead Investor / Acquirer

Bain Capital Life Sciences

Lead Investor / Acquirer

Samsara Biocapital

Lead Investor / Acquirer

Omega Funds

Lead Investor / Acquirer

Jeito Capital

Lead Investor / Acquirer

MRL Ventures Fund

Lead Investor / Acquirer

Vertex Ventures

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series A prioritised

VC Funding

Newcells Biotech

£2,350,000

Feb 2024

VC Funding

HutanBio

£2,250,000

Jan 2024

VC Funding

Lottie

£17,253,062

Oct 2023

VC Funding

Skin Analytics

£4,000,000

Sept 2020

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.